Amicus Therapeutics (DE:AM6)
FRANKFURT:AM6

Amicus Stock Price & Analysis

0 Followers

AM6 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€5.83 - €12.60
Previous Close€10.88
Volume0.00
Average Volume (3M)126.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$354.70M
Total Debt (Recent Filing)$450.87M
Price to Earnings (P/E)N/A
Beta0.86
Next EarningsFeb 23, 2023
EPS Estimate-€0.11
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding280,945,247
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume126
Price to Book (P/B)-36.59
Price to Sales (P/S)9.46
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-20.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside19.90% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering6


Financials


AM6 FAQ

What was Amicus’s price range in the past 12 months?
Amicus lowest stock price was €5.83 and its highest was €12.60 in the past 12 months.
    What is Amicus’s market cap?
    Currently, no data Available
    When is Amicus’s upcoming earnings report date?
    Amicus’s upcoming earnings report date is Feb 23, 2023 which is in 86 days.
      How were Amicus’s earnings last quarter?
      Amicus released its earnings results on Nov 07, 2022. The company reported -€0.116 earnings per share for the quarter, beating the consensus estimate of -€0.183 by €0.067.
        Is Amicus overvalued?
        According to Wall Street analysts Amicus’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Amicus pay dividends?
          Amicus does not currently pay dividends.
          What is Amicus’s EPS estimate?
          Amicus’s EPS estimate is -€0.11.
            How many shares outstanding does Amicus have?
            Currently, no data Available
            What happened to Amicus’s price movement after its last earnings report?
            Amicus reported an EPS of -€0.116 in its last earnings report, beating expectations of -€0.183. Following the earnings report the stock price went down -2.641%.
              Which hedge fund is a major shareholder of Amicus?
              Among the largest hedge funds holding Amicus’s share is Perceptive Advisors LLC. It holds Amicus’s shares valued at 286M.

                ---

                Amicus Stock Smart Score

                6
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                1.32%
                12-Months-Change

                Fundamentals

                Return on Equity
                -103.69%
                Trailing 12-Months
                Asset Growth
                -20.61%
                Trailing 12-Months
                The Amicus Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Amicus Therapeutics

                Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                AbbVie
                Amgen
                Gilead Sciences
                Moderna
                Vertex Pharmaceuticals

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis